Regenxbio Inc(RGNX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RGNX Regenxbio Inc

盘前交易 07-10 09:17:44 EDT

15.65

+0.42

+2.76%

盘前15.47

-0.18-1.15%

09:17 EDT

最高15.75	最低14.92	成交量197.55万
今开15.37	昨收15.23	日振幅5.45%
总市值8.08亿	流通市值6.73亿	总股本5,161万
成交额3,051万	换手率4.59%	流通股本4,300万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RGNX","market":"US","secType":"STK","nameCN":"Regenxbio Inc","latestPrice":15.65,"timestamp":1783627200000,"preClose":15.23,"halted":0,"volume":1975543,"hourTrading":{"tag":"盘前","latestPrice":15.47,"preClose":15.65,"latestTime":"09:17 EDT","volume":2831,"amount":43532.575762,"timestamp":1783689461313,"change":-0.18,"changeRate":-0.011502,"amplitude":0.047917},"delay":0,"changeRate":0.027577150361129343,"floatShares":42998600,"shares":51612984,"eps":-5.598553,"marketStatus":"盘前交易","change":0.42,"latestTime":"07-10 09:17:44 EDT","open":15.37,"high":15.75,"low":14.92,"amount":30512255.708371002,"amplitude":0.054498,"askPrice":15.67,"askSize":1500,"bidPrice":15.38,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-5.598553,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783690200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1442462400000,"exchange":"NASDAQ","adjPreClose":15.65,"preHourTrading":{"tag":"盘前","latestPrice":15.47,"preClose":15.65,"latestTime":"09:17 EDT","volume":2831,"amount":43532.575762,"timestamp":1783689461313,"change":-0.18,"changeRate":-0.011502,"amplitude":0.047917},"postHourTrading":{"tag":"盘后","latestPrice":15.5,"preClose":15.65,"latestTime":"19:58 EDT","volume":10254,"amount":159859.5088,"timestamp":1783641491159,"change":-0.15,"changeRate":-0.009585,"amplitude":0.038339},"volumeRatio":0.6122078688729623,"optionData":{"bulkOrders":[{"symbol":"RGNX","call":true,"expireDate":1784260800000,"strike":"10.0","timestamp":1783612967124,"price":5.1,"volume":1050,"amount":535500,"type":"+"}]},"impliedVol":0.8091,"impliedVolPercentile":0.392},"requestUrl":"/m/hq/s/RGNX/wiki","defaultTab":"wiki","newsList":[{"id":"1179995011","title":"Regenxbio Inc预计7月召开A类会议 并计划会后于2026年第三季度迅速重新提交BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=1179995011","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179995011?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:40","pubTimestamp":1782128441,"startTime":"0","endTime":"0","summary":"Regenxbio Inc 近日表示，公司预计将在今年7月与美国食品药品监督管理局（FDA）举行一次A类会议。此次会议旨在就相关生物制品许可申请（BLA）进行关键讨论。\n在会议结束后，公司计划迅速行动，于2026年第三季度内重新提交该BLA申请。这一时间表凸显了公司推进其研发管线的决心与效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","RGNX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154362997","title":"Regenxbio：与FDA就Naxsunli潜在加速批准所需后续步骤达成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1154362997","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154362997?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:40","pubTimestamp":1782128436,"startTime":"0","endTime":"0","summary":"Regenxbio公司表示，已与美国食品药品监督管理局（FDA）就基因疗法Naxsunli获得潜在加速批准所需的后续步骤达成共识。公司发言人指出，双方已明确后续行动方向，为推进该疗法的审评进程奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","RGNX","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126499596","title":"Regenxbio宣布与FDA就Navsunli™加速批准BLA重新提交路径达成一致；首款潜在MPS II基因疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1126499596","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126499596?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:31","pubTimestamp":1782127877,"startTime":"0","endTime":"0","summary":"Regenxbio公司近日宣布，已与美国食品药品监督管理局就Navsunli™生物制品许可申请的重新提交路径达成一致，旨在寻求加速批准。该疗法有望成为针对黏多糖贮积症II型的首款基因疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4563","RGNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117785366","title":"消息称FDA将推翻罕见病药物否决决定，Regenxbio盘前股价飙升11.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117785366","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117785366?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:56","pubTimestamp":1782125808,"startTime":"0","endTime":"0","summary":"有报道称，美国食品药品监督管理局将撤销此前对Regenxbio公司罕见病治疗药物的否决决定。受此利好消息推动，Regenxbio股价在盘前交易时段应声大涨11.2%。\n这一戏剧性反转为这家生物技术公司带来了新的希望。市场情绪迅速转向乐观，投资者纷纷押注该药物最终有望获得监管批准。若消息属实，将标志着公司研发管线的重要突破。\n罕见病药物领域向来具有高风险、高回报的特性。监管态度的转变往往能瞬间重塑市场格局。本次股价的剧烈波动，正反映了投资者对监管风向变化的敏锐捕捉。\n目前，相关各方尚未对报道内容发表正式评论。但资本市场的热烈反应已清晰表明，市场预期正在发生根本性转变。后续进展值得密切关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","RGNX","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125600512","title":"Regenxbio公布关键性III期AFFINITY Duchenne®研究中RGX-202的积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1125600512","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125600512?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:01","pubTimestamp":1778756516,"startTime":"0","endTime":"0","summary":"生物技术公司Regenxbio Inc宣布，其针对杜氏肌营养不良症（DMD）的研究性基因疗法RGX-202，在关键性III期AFFINITY Duchenne®研究中取得了积极的顶线结果。\n数据显示，该疗法达到了研究的主要终点，在患者运动功能的关键评估指标上表现出具有统计学意义和临床意义的改善。安全性方面，RGX-202的耐受性普遍良好，观察到的不良事件与先前研究一致。\n这一积极结果为RGX-202的后续监管申请奠定了坚实基础。公司计划基于这些数据，与全球监管机构进行讨论，以推动该疗法早日惠及DMD患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4563","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195469481","title":"Regenxbio Inc 三期研究达到主要终点，93%患者微肌营养不良蛋白表达超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195469481","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195469481?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:01","pubTimestamp":1778756514,"startTime":"0","endTime":"0","summary":"Regenxbio公司宣布，其三期临床研究成功达到主要终点。数据显示，高达93%的受试患者体内微肌营养不良蛋白的表达水平超过了10%。这一关键成果标志着该公司在基因疗法领域取得了重要进展，为相关疾病的治疗带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4505","BK4139","RGNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187547111","title":"Regenxbio公司RGX-202疗法显示微肌营养不良蛋白表达与功能改善显著相关","url":"https://stock-news.laohu8.com/highlight/detail?id=1187547111","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187547111?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:01","pubTimestamp":1778756494,"startTime":"0","endTime":"0","summary":"Regenxbio公司公布的最新数据显示，其基因疗法候选产品RGX-202在临床试验中展现出令人鼓舞的结果。研究证实，患者体内微肌营养不良蛋白的表达水平与其运动功能的临床改善之间存在显著的正相关性。\n这一发现为RGX-202治疗杜氏肌营养不良症的有效性提供了关键的科学依据，表明提升目标蛋白的表达可直接转化为患者获益。公司将继续推进该疗法的临床开发，以评估其长期安全性与疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4139","BK4505","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129931777","title":"Regenxbio Inc 将继续依据现有再授权协议向葛兰素史克支付从被再授权方获得的款项 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1129931777","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129931777?lang=zh_cn&edition=full","pubTime":"2026-03-21 05:20","pubTimestamp":1774041636,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件，生物技术公司Regenxbio Inc已确认，将继续依据其与制药巨头葛兰素史克之间现有的再授权协议，向后者支付从被再授权方处收到的相关款项。\n该安排明确了Regenxbio在相关知识产权商业化进程中的财务义务，确保了协议条款的持续履行。此举反映了双方长期合作关系的稳定性，以及对既定合约条款的遵守。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU1228905037.USD","LU1228905540.USD","LU0211331839.USD","LU1645745479.HKD","SG9999001176.SGD","LU0289739699.SGD","LU1202635105.USD","LU0321505439.SGD","LU1064927863.SGD","LU1481600234.SGD","LU0058720904.USD","LU0203345920.USD","IE0034235071.USD","LU0321505868.SGD","LU0225771236.USD","LU0971552673.USD","LU0203347892.USD","LU1400636574.HKD","LU0109981661.USD","LU1098665638.USD","LU1400636657.SGD","LU0161305163.EUR","LU1983299246.USD","SGXZ57979304.SGD","LU0545562505.USD","BK5011","LU0575583348.USD","LU1046248800.SGD","LU1487256676.USD","LU1302929846.USD","IE00BWDBJ516.SGD","LU0971552830.HKD","LU1035777561.USD","LU1309081286.SGD","IE00B3T34201.USD","IE00BQJZX424.USD","BK4563","LU0306806265.USD","RGNX","LU1400636491.USD","LU0985481810.HKD","SG9999001176.USD","LU1481599808.USD","LU1015430645.USD","LU1670756490.USD","SG9999013999.USD","BK4505","BK4139","GSK.UK","LU0306807586.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157978172","title":"Regenxbio Inc将向葛兰素史克支付1000万美元 以解决分许可费支付不足指控","url":"https://stock-news.laohu8.com/highlight/detail?id=1157978172","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157978172?lang=zh_cn&edition=full","pubTime":"2026-03-21 05:19","pubTimestamp":1774041550,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）的一份文件披露，生物技术公司Regenxbio Inc（RGNX）将向制药巨头葛兰素史克（GSK.UK）支付1000万美元，以了结后者关于其分许可费用支付不足的指控。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","LU0289739699.SGD","LU0225771236.USD","IE00BQJZX424.USD","LU0203347892.USD","LU1035777561.USD","LU1046248800.SGD","LU1983299246.USD","LU1064927863.SGD","BK4563","LU0545562505.USD","LU1202635105.USD","LU1228905037.USD","BK4505","LU0985481810.HKD","LU1015430645.USD","LU1400636574.HKD","LU1400636657.SGD","LU0971552830.HKD","LU1228905540.USD","IE00B3T34201.USD","LU1302929846.USD","LU1400636491.USD","BK4139","LU1645745479.HKD","LU0161305163.EUR","SG9999013999.USD","LU0321505439.SGD","SGXZ57979304.SGD","LU0225284248.USD","LU0203345920.USD","LU1670756490.USD","LU0306807586.USD","LU0575583348.USD","GSK.UK","LU1098665638.USD","LU1481600234.SGD","LU0306806265.USD","BK5011","IE0034235071.USD","LU0211331839.USD","LU1309081286.SGD","IE00BWDBJ516.SGD","SG9999001176.USD","LU1481599808.USD","LU1487256676.USD","LU0109981661.USD","SG9999001176.SGD","LU0058720904.USD","LU0971552673.USD","LU0321505868.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162955575","title":"Regenxbio Inc与葛兰素史克达成和解与免责协议 日期锁定2026年3月18日——美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1162955575","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162955575?lang=zh_cn&edition=full","pubTime":"2026-03-21 05:18","pubTimestamp":1774041494,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新文件显示，生物技术公司Regenxbio Inc已与制药巨头葛兰素史克（GlaxoSmithKline）正式签署和解与免责协议。该协议于2026年3月18日生效，标志着双方就相关争议达成最终解决方案。\n此项协议的签署终止了双方此前存在的法律争议，为未来可能的合作清除了障碍。文件未披露具体和解金额及协议细节，但明确双方均同意免除彼此在此事上的所有追索权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4139","BK4505","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612232606","title":"Regenxbio Inc.盘中异动 股价大涨5.06%报8.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612232606","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612232606?lang=zh_cn&edition=full","pubTime":"2026-02-20 04:08","pubTimestamp":1771531713,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日04时08分，Regenxbio Inc.股票出现异动，股价大幅上涨5.06%。截至发稿，该股报8.30美元/股，成交量46.1061万股，换手率0.91%，振幅8.54%。Regenxbio Inc.股票所在的生物技术行业中，整体跌幅为0.39%。Regenxbio Inc.公司简介：Regenxbio Inc 是一家生物技术公司。Regenxbio 平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022004083495417a16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022004083495417a16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4563","RGNX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610362425","title":"FDA拒绝Regenxbio的亨特综合征基因疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2610362425","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610362425?lang=zh_cn&edition=full","pubTime":"2026-02-11 00:04","pubTimestamp":1770739440,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Regenxbio（RGNX）周二早盘大跌13.3%，此前美国食品药品管理局（FDA）对该公司开发的、针对亨特综合的一次性基因疗法RGX-121发出完整回复函，指出对替代终点和对照可比性的担忧。\n　　亨特综合是由于水痘-带状疱疹病毒再激活引发的周围性面瘫。\n　　Regenxbio公司称计划召开A类会议并可能重新提交申请。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-11/doc-inhmkcry1109040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","RGNX","BK4505","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152068358","title":"FDA拒绝批准罕见病基因疗法，Regenxbio股价盘前重挫14.2%至8.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152068358","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152068358?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:11","pubTimestamp":1770714676,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）否决了Regenxbio公司针对罕见病开发的基因疗法，导致该公司股价在盘前交易中暴跌14.2%，跌至每股8.85美元。这一监管挫折直接冲击了市场信心，反映出投资者对基因疗法商业化前景的担忧。\n此次FDA的否决决定不仅凸显了生物技术公司面临严格的审批环境，也可能延缓Regenxbio在该治疗领域的进展。股价的急剧下跌预示着市场对公司短期业绩和研发路径的重新评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4563","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609422285","title":"Regenxbio Inc.盘中异动 大幅上涨5.70%报10.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609422285","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609422285?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:31","pubTimestamp":1770388299,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日22时31分，Regenxbio Inc.股票出现异动，股价快速拉升5.70%。截至发稿，该股报10.85美元/股，成交量1.5655万股，换手率0.03%，振幅0.58%。Regenxbio Inc.股票所在的生物技术行业中，整体涨幅为0.36%。Regenxbio Inc.公司简介：Regenxbio Inc 是一家生物技术公司。Regenxbio 平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206223139a48514ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206223139a48514ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RGNX","BK4563","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608810140","title":"Regenxbio Inc.盘中异动 急速下跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608810140","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608810140?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:38","pubTimestamp":1770043131,"startTime":"0","endTime":"0","summary":"北京时间2026年02月02日22时38分，Regenxbio Inc.股票出现波动，股价急速下跌5.11%。截至发稿，该股报10.59美元/股，成交量5.9816万股，换手率0.12%，振幅3.41%。Regenxbio Inc.股票所在的生物技术行业中，整体跌幅为0.03%。Regenxbio Inc.公司简介：Regenxbio Inc 是一家生物技术公司。Regenxbio 平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020222385197a48664&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020222385197a48664&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4563","BK4505","RGNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607202743","title":"Regenxbio Inc.盘中异动 大幅跳水5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607202743","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607202743?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:52","pubTimestamp":1769784731,"startTime":"0","endTime":"0","summary":"北京时间2026年01月30日22时52分，Regenxbio Inc.股票出现异动，股价急速下跌5.09%。截至发稿，该股报11.01美元/股，成交量8.4117万股，换手率0.17%，振幅2.84%。Regenxbio Inc.股票所在的生物技术行业中，整体跌幅为0.40%。Regenxbio Inc.公司简介：Regenxbio Inc 是一家生物技术公司。Regenxbio 平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026013022521197a434e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026013022521197a434e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","BK4139","RGNX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187656016","title":"Regenxbio展望2026年关键催化剂 公布杜氏肌营养不良基因疗法长期积极功能数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1187656016","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187656016?lang=zh_cn&edition=full","pubTime":"2026-01-12 04:01","pubTimestamp":1768161689,"startTime":"0","endTime":"0","summary":"Regenxbio Inc近日披露了公司研发管线的重要进展，重点强调了2026年将迎来的关键里程碑事件。与此同时，其领先的杜氏肌营养不良症基因治疗项目公布了令人鼓舞的长期功能性结果数据。\n这些积极成果为项目后续开发注入了强劲动力，展现了该疗法在改善患者功能方面的持久潜力。公司正积极推进临床研究，为未来关键节点的达成奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4563","BK4139","RGNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518618275","title":"Regenxbio Inc.盘中异动 大幅下跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518618275","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518618275?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:43","pubTimestamp":1741617829,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时43分，Regenxbio Inc.股票出现波动，股价快速跳水5.05%。Regenxbio Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3488.18%、763.71%、655.35%，振幅较大的相关个股有Scisparc Ltd.、Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc，振幅分别为45.06%、41.36%、40.33%。Regenxbio Inc.公司简介：Regenxbio Inc是一家生物技术公司。Regenxbio平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022434998a2aef9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022434998a2aef9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RGNX","BK4505","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517924359","title":"Regenxbio Inc.盘中异动 快速上涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517924359","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517924359?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:54","pubTimestamp":1741208046,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时54分，Regenxbio Inc.股票出现波动，股价大幅拉升5.15%。截至发稿，该股报6.23美元/股，成交量59.3174万股，换手率1.20%，振幅6.25%。Regenxbio Inc.股票所在的生物技术行业中，整体涨幅为1.91%。Regenxbio Inc.公司简介：Regenxbio Inc是一家生物技术公司。Regenxbio平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306045406a261314c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306045406a261314c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RGNX","BK4505","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516670723","title":"Regenxbio Inc.盘中异动 早盘股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516670723","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516670723?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:52","pubTimestamp":1741099954,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时52分，Regenxbio Inc.股票出现波动，股价急速跳水5.06%。截至发稿，该股报5.62美元/股，成交量11.8075万股，换手率0.24%，振幅3.38%。Regenxbio Inc.股票所在的生物技术行业中，整体涨幅为0.32%。Regenxbio Inc.公司简介：Regenxbio Inc是一家生物技术公司。Regenxbio平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422523496394b43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422523496394b43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4563","BK4139","RGNX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regenxbio.com","stockEarnings":[{"period":"1week","weight":0.1785},{"period":"1month","weight":1.4685},{"period":"3month","weight":0.7784},{"period":"6month","weight":0.0727},{"period":"1year","weight":0.7067},{"period":"ytd","weight":0.0868}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0199},{"period":"3month","weight":0.1063},{"period":"6month","weight":0.083},{"period":"1year","weight":0.2045},{"period":"ytd","weight":0.1023}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Regenxbio Inc.于2008年7月16日成立。该公司是一家领先的生物技术公司，专注于重组腺相关病毒基因疗法的开发、商业化和授权。在AAV基因疗法中，病毒基因从AAV（一种小型、非致病性感冒病毒）中移除，从而构建一种称为载体的生物递送工具。然后，将治疗性基因序列插入其中，形成重组载体。该公司拥有专有的AAV基因递送平台，该平台包含100多种新型AAV载体的独家使用权，其中包括AAV7、AAV8、AAV9和AAVrh10。公司的使命是基于其NAV技术平台，开发和商业化直接注射到体内（即体内给药）的基因治疗产品，从而改善患有严重疾病且存在重大未满足医疗需求的患者的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.091067},{"month":2,"riseRate":0.272727,"avgChangeRate":0.000501},{"month":3,"riseRate":0.545455,"avgChangeRate":0.007203},{"month":4,"riseRate":0.636364,"avgChangeRate":0.038941},{"month":5,"riseRate":0.272727,"avgChangeRate":-0.040299},{"month":6,"riseRate":0.636364,"avgChangeRate":0.107793},{"month":7,"riseRate":0.454545,"avgChangeRate":0.026267},{"month":8,"riseRate":0.4,"avgChangeRate":0.017624},{"month":9,"riseRate":0.6,"avgChangeRate":0.07131},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.060741},{"month":11,"riseRate":0.727273,"avgChangeRate":0.164969},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.05132}],"exchange":"NASDAQ","name":"Regenxbio Inc","nameEN":"Regenxbio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regenxbio Inc(RGNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Regenxbio Inc(RGNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Regenxbio Inc,RGNX,Regenxbio Inc股票,Regenxbio Inc股票老虎,Regenxbio Inc股票老虎国际,Regenxbio Inc行情,Regenxbio Inc股票行情,Regenxbio Inc股价,Regenxbio Inc股市,Regenxbio Inc股票价格,Regenxbio Inc股票交易,Regenxbio Inc股票购买,Regenxbio Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regenxbio Inc(RGNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Regenxbio Inc(RGNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}